Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Daily Low-Dose chemo tested for patients with no other options

NCT ID NCT00420563

Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 18, 2026 · Updated 3 times

Summary

This study tested two treatments for people with advanced cancer who cannot have standard therapy. One group took a low-dose chemotherapy pill (cyclophosphamide) daily, and the other took a hormone pill (megestrol). The goal was to see which treatment could slow cancer growth for at least two months. The trial enrolled 88 adults with various cancers (except breast cancer) and measured how long the cancer stayed under control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cyclophosphamide (low-dose chemotherapy) and megestrol (hormone therapy)
What this could lead to
If successful, this could offer a gentle, long-term chemotherapy option for patients with advanced cancer who have run out of standard treatments.
What could go wrong
This is a small, early-phase trial with only 88 participants. The benefit may be modest, and side effects like low blood counts or blood clots are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

88 people

The number who actually took part.

Started

Sep 2009

Finished

Jan 2011

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> or = 18 * PS-WHO \< or = 1 * Histologically proven cancer * No other therapeutic proposal * Treatment can be orally taken * Radiologic proof of evolutive character of the disease * Effective contraception Exclusion Criteria: * Hypercalcemia ( Ca \> 2.65 mmol/l) * Breast cancer * Thrombosis or pulmonary embolism * Dysphagia, malabsorption * Polynuclear neutrophil leukocytes \< 1000/mm3 * Treatment with Tegretol * Active and uncontrolled infection * Evolutive psychiatric disease * Pregnant or lactating woman

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer

Contacts and locations

Locations

  • Centre Hospitalier Regional - Dermatology

    Lille, 59035, France

  • Centre Hospitalier Regional - Oncology

    Lille, 59035, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Hopital Saint Vincent

    Lille, 59020, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.